News Updates
Scope

Thu, May 14, 2026

1 updates
ZURA
7:30 AM

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev. --(BUSINESS WIRE)--May 14, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

zurabio.com

Wed, May 13, 2026

1 updates

Thu, May 7, 2026

1 updates

Mon, May 4, 2026

1 updates
ZURA
4:05 PM

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev. --(BUSINESS WIRE)--May 4, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

zurabio.com

Thu, Mar 19, 2026

1 updates

Thu, Mar 5, 2026

1 updates

Mon, Mar 2, 2026

1 updates
ZURA
6:30 AM

Zura Bio to Participate in Upcoming Investor Conferences

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 2, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

zurabio.com